Literature DB >> 17088683

18F-FDG PET imaging in assessing exudative pleural effusions.

Bernard C Duysinx1, Marie-Paule Larock, Delphine Nguyen, Jean-Louis Corhay, Thierry Bury, Roland Hustinx, Renaud Louis.   

Abstract

BACKGROUND: This study evaluates the accuracy of [F]fluorodeoxyglucose positron emission tomography (F-FDG PET) imaging with semi-quantitative analysis for differentiating benign from malignant pleural exudates and for guiding the search for the primary tumour of pleural metastases.
METHODS: Whole-body 18F-FDG PET was performed in 79 patients with exudative pleurisy. Standard uptake values were normalized for body weight, body surface area, lean body mass (SUVbw, SUVbsa, SUVlbm) with and without correction for blood glucose levels. Thoracoscopy was systematically performed to reveal pathological diagnosis.
RESULTS: All SUVs were significantly higher in all malignant pleural diseases (n = 51) than in benign (n = 28) (P < 0.001). Moreover SUVs were greater in the pleural metastases from pulmonary primaries (n = 25) and in mesotheliomas (n = 8) than in extrathoracic primaries (n = 18) (P < 0.01) with no significant difference between lung cancers and mesotheliomas. Receiver operating curve (ROC) analysis between benign and malignant lesions showed areas under the curves that ranged from 0.803 (SUVbsa g) to 0.863 (SUVbw). The cut-off value for SUVbw which gave the best accuracy (82.3%) was 2.2. When comparing thoracic with extrathoracic primaries the highest accuracy (80.4%) was found for a cut-off value of 2.6.
CONCLUSION: Semi-quantitative analysis of 18F-FDG PET imaging helps to differentiate malignant from benign pleural exudates and to distinguish between thoracic or extrathoracic primaries.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17088683     DOI: 10.1097/01.mnm.0000243366.96012.c0

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  8 in total

Review 1.  A Primer on the Management of Pleural Effusions.

Authors:  William Bremer; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2019-02-05       Impact factor: 1.513

Review 2.  Diagnostic imaging in the preoperative management of lung cancer.

Authors:  Kazuhiro Imai; Yoshihiro Minamiya; Hajime Saito; Satoru Motoyama; Yusuke Sato; Aki Ito; Kei Yoshino; Satoshi Kudo; Shinogu Takashima; Yasushi Kawaharada; Nobuyasu Kurihara; Kimito Orino; Jun-Ichi Ogawa
Journal:  Surg Today       Date:  2013-07-10       Impact factor: 2.549

Review 3.  Pleural effusion: diagnosis, treatment, and management.

Authors:  Vinaya S Karkhanis; Jyotsna M Joshi
Journal:  Open Access Emerg Med       Date:  2012-06-22

4.  [Clinical role of F-18 FDG PET/CT in differentiating malignant and benign pleural effusion in patients with lung cancer].

Authors:  Riqiang Liao; Xuening Yang; Siyun Wang; Qing Zhou; Qiang Nie; Wenzhao Zhong; Song Dong; Yilong Wu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-11

5.  Development and validation of the PET-CT score for diagnosis of malignant pleural effusion.

Authors:  Min-Fu Yang; Zhao-Hui Tong; Zhen Wang; Ying-Yi Zhang; Li-Li Xu; Xiao-Juan Wang; Wan Li; Xiu-Zhi Wu; Wen Wang; Yu-Hui Zhang; Tao Jiang; Huan-Zhong Shi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-03-22       Impact factor: 9.236

6.  The diagnostic role of glycosaminoglycans in pleural effusions: a pilot study.

Authors:  Rozina Vavetsi; Stefanos Bonovas; Paraskevi Polizou; Chrysanthi Papanastasopoulou; Georgia Dougekou; Nikolaos M Sitaras
Journal:  BMC Pulm Med       Date:  2009-02-18       Impact factor: 3.317

Review 7.  Staging non-small cell lung cancer.

Authors:  Leslie Eisenbud Quint
Journal:  Cancer Imaging       Date:  2007-10-22       Impact factor: 3.909

8.  Diagnostic Ability of FDG-PET/CT in the Detection of Malignant Pleural Effusion.

Authors:  Reiko Nakajima; Koichiro Abe; Shuji Sakai
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.